Procedures and Therapies

CMXI’s Aldagen acquisition is no exit; stem cell payoff is still down the road

9 Feb 2012

Cytomedix‘s (OTC:CMXI) Aldagen acquisition signaled the company’s intention to establish a strong presence in regenerative medicine therapies and the deal fills needs for both companies. Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective [...]

Syneron's elure Advanced Skin Lighteningâ„¢ Products Become Leading Solution for Hyperpigmentation

9 Feb 2012

LINCOLNSHIRE, Ill., Feb. 9, 2012 /PRNewswire/ -- Board Certified Dermatologist, Dr. Amy Forman Taub, a leading, nationally recognized expert in anti-aging products, treatments and technology, announces ...

BioMimetic Therapeutics, Inc. to Introduce Augmatrixâ„¢ Biocomposite Bone Graft Product Line at AAOS

8 Feb 2012

BioMimetic Therapeutics, Inc. today announced it will introduce Augmatrixâ„¢ Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distrib